Pelthos Therapeutics Inc. (PTHS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 58/100 (HIGH), 18.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.4% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
- Pelthos (PTHS) Q2 2026 Earnings Call Transcript
- Pelthos Therapeutics Inc (PTHS) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as ...
- Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
- Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
- Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
- Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
- Pelthos Therapeutics Q2 Earnings Call Highlights
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Pelthos Therapeutics Inc..
Full PTHS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.